Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (235)	1/28/1998 9:02:00 PM
From: John Wright	Read Replies (1) \| Respond to of 1494

John, thanks for the good news update. Also some interesting and positive comments from Paul Freiman i.e. "....and I expect it to generate considerable interest in the pharmaceutical community. We are now in negotiations with potential partners regarding collaborations...." Thoughts, opinions, anyone? John

To: Dr. John M. de Castro who wrote (235)	1/28/1998 9:38:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 1494

The P value is probably wrong (less than 0.10) should be 0.01 to be statistically significant. Good news. The lack of action in post herpetic (varicella/zoster) neuralgia is interesting since the phisiology is quite different to the diabetic cases. Probably dynorphin A will be more effective in pain reduction. Could Memantine protect the diabetic patients before all the damage or halt the ongoing process? They are trying to use it as a central neuroprotective. Could the pain relief be an early evidence of this protective effect? Just for the fun of thinking and guessing Lets see how the market like it.